accountWhen Pfizer Inc. abandoned a cholesterol pill four years ago after spending $1 billion to develop it, Richard Clark , Merck & Co. ’s chief executive officer, was tempted to give up on a similar drug in testing.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Merck's Risky Bet on Heart Drugs May Yield Lipitor-Like Success - Bloomberg
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account